Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
CA14161Y2006
Sat, 14.05.2022
Cardiol Therapeutics Inc.
Upcoming Investor Event:
Cardiol Therapeutics Inc. to present at digital International Investment
Forum (IIF)
On May 19, the IIF International Investment Forum will take place. At this
forum, Cardiol Therapeutics Inc. will also present its business model and
current business development.
Presentation slot:
Cardiol Therapeutics Inc. (ISIN: CA14 [ … ]
Thu, 10.02.2022
Cardiol Therapeutics Inc.
Upcoming Investor Event:
Cardiol Therapeutics to present at digital International Investment Forum
(IIF)
On February 17, the IIF International Investment Forum will take place. At
this forum, Cardiol Therapeutics will also present its business model and
current business development.
Presentation slot:
Cardiol Therapeutics Inc. (ISIN: CA14161Y2 [ … ]
Tue, 16.11.2021
Cardiol Therapeutics
GBC AG to present an investor round table conference call with Cardiol
Therapeutics and will present latest development.
With the completion of the Public Offering, the company will have raised
more than $ 52.4 million in cash. Included is $ 2.4 million from the
warrants' accelerated expiration date of June 4, 2020. On November 2nd, the
company [ … ]
Mon, 11.10.2021
Cardiol Therapeutics
Upcoming Investor Event:
Cardiol Therapeutics to present at digital International Investment Forum
(IIF)
On October 14, the IIF International Investment Forum will take place. At
this fo-rum, Cardiol Therapeutics will also present its business model and
current business development.
Presentation slot:
Cardiol Therapeutics Inc.
09.00 am EDT*
[ … ]
Mon, 13.09.2021
Cardiol Therapeutics Inc.
Die FDA hat die Freigabe zur Durchführung der klinischen Phase-II-Studie
für CardiolRX(TM) bei akute Myokarditis erteilt.
Dr. Guillermo Torre-Amione wurde zum neuen Vorsitzenden ernannt
Die Aktien der Cardiol Therapeutics sind nun auch an der NASDAQ gelistet.
Am 24. August erhielt Cardiol Therapeutics von der FDA die Freigabe des
IND-A [ … ]
Thu, 09.09.2021
Cardiol Therapeutics
On August 24th, Cardiol Therapeutics received FDA Clearance of
Investigational New Drug (IND) Application for Phase II Clinical Trial of
CardiolRx(TM) for Acute Myocarditis.
Phase II trial details
The company's Investigational New Drug (IND) application approval allows
Cardiol Therapeutics to commence a Phase II, multi-center, double-blind,
ra [ … ]
Fri, 13.08.2021
Cardiol Therapeutics
Cardiol Therapeutics successful NASDAQ listing
NASDAQ Capital Market LLC has granted Cardiol final approval to list its
common shares on NASDAQ. On August 10, 2021, the Company's shares started
trading under the ticker 'CRDL'.
David Elsley, President & CEO of Cardiol Therapeutics, said, 'Listing on
NASDAQ is a major milestone for our Compa [ … ]
Wed, 23.06.2021
Cardiol Therapeutics
One Product in two formulations, heart disease treatments in the making
Cardiol Therapeutics provides leadership in therapeutic trials using
Cannabidiol to take advantage of major opportunities in inflammatory heart
disease.
The company has an exclusive manufacturing agreement for a Cannabidiol
pharmaceutical formulation which is highly concen [ … ]
Thu, 22.04.2021
Cardiol Therapeutics
The Company announced topline results from its Phase I Single and Multiple
Ascending Dose Clinical Trial of CardiolRx(TM). CardiolRx is a
pharmaceutically produced oral cannabidiol formulation being developed for
the treatment of acute and chronic inflammation associated with heart
disease. These results positively support Cardiol Therapeutics' pr [ … ]
Mon, 29.03.2021
Cardiol Therapeutics
GBC Research Watchlist: Cardiol Therapeutics Inc.
'The right moment to participate in this exciting growth story'
Cortalex - The purest form of CBD, no THC. It matters.
For many patient segments, CBD medication can be linked to the possibility
of becoming intoxicated by THC. For children, young adults under 25,
workers that cannot be intoxic [ … ]